Quantcast
Home > Quotes > HJLI

Hancock Jaffe Laboratories, Inc. Common Stock (HJLI) Quote & Summary Data

HJLI 
$2.3617
*  
0.0617
2.68%
Get HJLI Alerts
*Delayed - data as of Mar. 19, 2019 11:27 ET  -  Find a broker to begin trading HJLI now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    HJLI Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 2.33 / $ 2.39
1 Year Target
Today's High / Low
$ 2.49 / $ 2.211
Share Volume
101,741
50 Day Avg. Daily Volume
162,989
Previous Close
$ 2.30
52 Week High / Low
$ 5.64 / $ 1.31
Market Cap
33,246,496
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
3.13

Intraday Chart

Shares Traded

Share Volume:
101,741
50 Day Avg. Daily Volume:
162,989

Trading Range

The current last sale of $2.3617 is 80.28% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 2.49 $ 5.64
 Low: $ 2.211 $ 1.31

Company Description (as filed with the SEC)

Hancock Jaffe Laboratories, Inc. is a development stage company developing tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. HJLI's products are being developed to address large unmet medical needs by either offering treatments where none currently exist or by substantially increasing the existing standards of care. Our two lead products which we are developing are the VenoValve┬«, a porcine based device to be surgically implanted in the deep venous system of the leg to treat a debilitating condition called chronic venous insufficiency ("CVI"), and the CoreoGraft┬«, a bovine based conduit to be used to revascularize the heart during coronary artery bypass graft ("CABG") surgeries. Our third product is a Bioprosthetic Heart Valve ("BHV") which has the potential to be used for pediatric heart valve recipients.  ... More ...  

Nasdaq Official Price

Open Price:
$ 2.26
Open Date:
Mar. 19, 2019
Close Price:
$ 2.30
Close Date:
Mar. 18, 2019


Research Brokers before you trade

Want to trade FX?

Analyst Info